RhumbLine Advisers’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$85.8K Sell
122,294
-15,839
-11% -$14.8K ﹤0.01% 3463
2025
Q4
$214K Sell
138,133
-10,484
-7% -$16.7K ﹤0.01% 3153
2025
Q3
$235K Sell
148,617
-1,843
-1% -$3.2K ﹤0.01% 3144
2025
Q2
$328K Sell
150,460
-2,574
-2% -$6.23K ﹤0.01% 2931
2025
Q1
$418K Sell
153,034
-621
-0.4% -$2.45K ﹤0.01% 2684
2024
Q4
$639K Buy
153,655
+2,402
+2% +$9.08K ﹤0.01% 2508
2024
Q3
$588K Sell
151,253
-6,363
-4% -$26.8K ﹤0.01% 2593
2024
Q2
$618K Buy
157,616
+20,864
+15% +$89.8K ﹤0.01% 2521
2024
Q1
$573K Buy
136,752
+3,901
+3% +$18.3K ﹤0.01% 2579
2023
Q4
$624K Buy
132,851
+1,443
+1% +$5.62K ﹤0.01% 2537
2023
Q3
$410K Sell
131,408
-91
-0.1% -$366 ﹤0.01% 2729
2023
Q2
$604K Sell
131,499
-3,644
-3% -$16.7K ﹤0.01% 2574
2023
Q1
$669K Buy
135,143
+7,072
+6% +$34.8K ﹤0.01% 2304
2022
Q4
$699K Buy
128,071
+1,484
+1% +$9.1K ﹤0.01% 2307
2022
Q3
$823K Buy
126,587
+7,403
+6% +$41.3K ﹤0.01% 2250
2022
Q2
$564K Buy
119,184
+14,306
+14% +$70.5K ﹤0.01% 2436
2022
Q1
$733K Buy
104,878
+11,184
+12% +$76.4K ﹤0.01% 2260
2021
Q4
$955K Buy
93,694
+82,957
+773% +$891K ﹤0.01% 2234
2021
Q3
$131K Buy
+10,737
New +$162K ﹤0.01% 2968

Other funds holding MXCT

RhumbLine Advisers's MXCT Position: Q1 2026 in Review

RhumbLine Advisers reduced its MaxCyte (MXCT) stake by 11% in Q1 2026, selling an estimated $14.8K and leaving 122,294 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3463.

RhumbLine Advisers first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $955K in Q4 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • RhumbLine Advisers held 122,294 shares of MaxCyte worth $85.8K as of Q1 2026.
  • RhumbLine Advisers sold 15,839 MaxCyte shares in Q1 2026, an estimated $14.8K.
  • MaxCyte made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3463 holding.
  • RhumbLine Advisers first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
  • RhumbLine Advisers's MaxCyte position peaked at $955K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.